Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company employs 10 full-time employees The company went IPO on 2021-07-16. The firm launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
RGC stock price ended at $6.09 on 火曜日, after dropping 1.62%
On the latest trading day Jun 30, 2026, the stock price of RGC fell by 1.62%, dropping from $6.01 to $6.09. During the session, the stock saw a volatility of 18.62%, with prices oscillating between a daily low of $5.80 and a high of $6.88. On the latest trading day, the trading volume for RGC rose by 41.4K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 441.4K shares were traded, with a market value of approximately $3.0B.
기술 분석에 따르면, Regencell Bioscience Holdings Ltd은 Sell의 종합 신호를 가지고 있습니다. Regencell Bioscience Holdings Ltd은 2개의 매수 신호, 0개의 중립 신호, 그리고 5개의 매도 신호를 가지고 있습니다.